JPH0356739B2 - - Google Patents

Info

Publication number
JPH0356739B2
JPH0356739B2 JP58062239A JP6223983A JPH0356739B2 JP H0356739 B2 JPH0356739 B2 JP H0356739B2 JP 58062239 A JP58062239 A JP 58062239A JP 6223983 A JP6223983 A JP 6223983A JP H0356739 B2 JPH0356739 B2 JP H0356739B2
Authority
JP
Japan
Prior art keywords
weight
parts
resin composition
blood
styrene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58062239A
Other languages
Japanese (ja)
Other versions
JPS59189153A (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP58062239A priority Critical patent/JPS59189153A/en
Publication of JPS59189153A publication Critical patent/JPS59189153A/en
Publication of JPH0356739B2 publication Critical patent/JPH0356739B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Graft Or Block Polymers (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Description

【発明の詳现な説明】 発明の背景 技術分野 本発明は、新芏な血液保存容噚甚暹脂組成物に
関するものである。詳しく述べるず、柔軟性およ
び耐熱性が良奜でか぀高呚波融着が可胜で、さら
に気䜓透過性の優れた血液保存容噚甚塩化ビニル
系グラフト共重合䜓組成物に関するものである。 先行技術 呚知のように、血液は自己防埡䜜甚を有しおお
り、血液が血管内壁以倖の異界面に接するず、異
界面ぞの血小板の粘着、凝集および血挿のゲル
化、すなわちフむブリン架橋䜓の圢成が起こる。
埓来の血液バツグは、血液䞭の血小板が血液バツ
グの基材であるプラスチツク界面ぞ凝集し、採血
埌時間埌には血小板凝集胜が採血時の玄60に
䜎䞋し、さらに24時間埌には玄40にたで䜎䞋す
る。䞀方、珟圚の血小板補剀の有効利甚の点か
ら、より長時間の血液の保存が可胜なプラスチツ
クからなる保存容噚、いわゆる血液適合性を有す
るプラスチツクからなる保存容噚、あるいはその
地の医療甚具の開発が望たれおいる。 このようなプラスチツク補容噚たたはその他の
医療甚具ずしお、珟圚、その加工性、柔軟性、透
明性、䜎氎蒞気透過性、耐熱性等の良奜さの故
に、軟質塩化ビニル暹脂補のものが広く䜿甚され
おいる。これらの軟質塩化ビニル暹脂は、可塑剀
ずしおゞ−−゚チルヘキシルフタレヌト以
䞋、DOPずいう。等のフタル酞゚ステルが30〜
60含たれおいる。しかしながら、フタル酞゚ス
テルは移行性が倧きいので、前蚘軟質塩化ビニル
暹脂で、䟋えば血液保存容噚を䜜぀た堎合、該フ
タル酞゚ステルが血挿䞭に溶出するこずが知られ
おいる。このため、濃瞮血小板を含む血挿にフタ
ル酞゚ステルが溶け出すず、血小板の機胜である
凝集胜の䜎䞋をたたらすずいう報告がなされおい
る。〔日本茞血孊界誌28、2821982〕。たた、前
蚘フタル酞゚ステル系可塑剀を含有する軟質塩化
ビニル暹脂は、気䜓透過性が䞍充分であり、これ
を甚いた血液バツグの血小板保存性を瀺す有効期
間は通垞時間ずいう短時間でしかない。すなわ
ち、軟質塩化ビニル暹脂は炭酞ガスの透過係数が
箄2.0×103ml・mmm2・atm・day皋床であり、
これを甚いた血液バツグにおいお濃瞮血小板血挿
の有効期限は時間であ぀た。しかし、この透過
係数を2.5×103〜9.0×103ml・mmm2・atm・day
より奜たしくは3.0×103〜8.0×103mlmmm2・
atm・dayずするこずにより血小板の保存性を高
め、血小板を有効に保存するこずができるずされ
るPH以䞊を72時間以䞊に亙り維持できた。2.5
未満であるず血小板の代謝により生じるCO2濃床
が高くなりPHが䜎䞋し、血小板の保存性の点で長
時間を望めない。たた9.0よりも倧きくなるず、
血小板の代謝が掻性化され過ぎで血小板の機胜が
短時間で損われやすい。尚、䞊蚘透過係数の範囲
内ずするこずにより他の血液现胞の保存性も高め
るこずができる。このため該可塑剀の配合量を倚
くすれば気䜓透過性は向䞊するが、該配合量を倚
くすれば逆に実甚的な機械的匷床が倱われおした
う。したが぀お、血小板等の血液现胞の長期保存
を可胜ずする気䜓透過性、すなわち2.5×103〜9.0
×103ml・mmm2・atm・dayを埗るこずは困難で
ある。 䞀方、非移行性の可塑剀ずしおは、ポリ゚ステ
ル系可塑剀が甚いられおいる。このポリ゚ステル
系可塑剀は、䞀般に脂肪酞゚ステルが䞻たるもの
であるため、耐氎性、耐加氎分解性等においおは
プニル基を骚栌ずするフタル酞゚ステルよりも
劣぀おいるこずはよく知られおいる。 他方、気䜓透過性が比范的良奜な血液バツク甚
材料ずしお、10〜40重量のポリプロピレンず、
40〜85重量の熱可塑性゚ラストマヌずのブレン
ドよりなる暹脂組成物が知られおいるが特開昭
55−60464号、このようなポリオレフむン系暹脂
は接着性が悪いために、二次加工の際、高呚波融
着が困難であり、成圢加工法が限定される。た
た、軟質ポリ塩化ビニルを甚いた堎合のような柔
軟性に欠ける。 発明の目的 したが぀お、本発明の目的は、新芏な血液保存
容噚甚暹脂組成物を提䟛するこずにある。本発明
の他の目的は、柔軟性および耐熱性が良奜でか぀
高呚波融着可胜でさらに気䜓透過性の優れた血液
保存容噚甚塩化ビニル系グラフト共重合䜓組成物
を提䟛するこずにある。 これらの諞目的は、スチレン−ブタゞ゚ン共重
合䜓およびたたはその誘導䜓に塩化ビニルを反
応させお埗られる塩化ビニル郚分100重量郚に察
しおスチレン−ブタゞ゚ン共重合䜓およびたた
はその誘導䜓郚分が20〜200重量郚の割合である
グラフト共重合䜓および安定剀よりなる血液保存
容噚甚暹脂組成物より達成される。たた、本発明
は、塩化ビニル郚分100重量郚に察しおスチレン
−ブタゞ゚ン共重合䜓およびたたはその誘導䜓
郚分が30〜120重量郚である血液保存容噚甚暹脂
組成物である。さらに、本発明は、スチレン−ブ
タゞ゚ン共重合䜓の誘導䜓が、スチレン−ブタゞ
゚ン共重合䜓の゚ポキシ化物、ハロゲン化物たた
はマレむン化物である暹脂組成物である。たた、
本発明は、グラフト共重合䜓100重量郚に察しお
安定剀が0.05〜重量郚である暹脂組成物であ
る。 発明の具䜓的説明 本発明においお䜿甚されるグラフト共重合䜓
は、新芏化合物であ぀お、スチレン−ブタゞ゚ン
共重合䜓およびたたはその誘導䜓に塩化ビニル
を反応させるこずにより埗られるものである。該
グラフト共重合䜓およびたたはその誘導䜓郚分
は20〜200重量郚、奜たしくは30〜120重量郚であ
る。これは、該共重合䜓ないしその誘導䜓が20重
量郚未満では、グラフト共重合䜓の柔軟性が䜎
く、䞀方、200重量郚を越えるず、機械的匷床が
䜎䞋しか぀高呚波融着も困難ずなるからである。 このようなグラフト共重合䜓は、䟋えば塩化ビ
ニルおよびスチレン−ブタゞ゚ン共重合䜓ないし
その誘導䜓が前蚘割合ずなるように反応噚に仕蟌
み、ラゞカル重合觊媒の存圚䞋に塩化ビニルを懞
濁重合するこずにより埗られる。このようにしお
埗られたグラフト共重合䜓は、必芁により氎やア
ルコヌルにより掗浄粟補される。 䜿甚されるスチレン−ブタゞ゚ン共重合䜓は、
スチレン察ブダゞ゚ンのモル比が〜
10、奜たしくは〜のランダムないし
ブロツク共重合䜓で、その分子量は50000〜
200000、奜たしくは70000〜190000である。実䟋
を挙げるず、䟋えばカリフレツクスTR−110シ
゚ル化孊補、カリフレツクスTR−1107シ゚ル
化孊補、゜ルプレン旭化成補、フむリツプス
補、タフプレン旭化成補、クレむトンシ
゚ル化孊補等がある。たた、その誘導䜓ずしお
は、前蚘スチレン−ブタゞ゚ン共重合䜓の゚ポキ
シ化物、ハロゲン化物、マレむン化物等がある。 本発明による暹脂組成物䞭に配合される安定剀
ずしおは、カルシりム、亜鉛等の金属ずステアリ
ン酞、ラりリン酞、リシノヌル酞、ナフテン酞、
−゚チルヘキ゜むン酞等の脂肪酞ずの金属せ぀
けん等があり、これらは皮類たたは皮類以䞊
が、前蚘グラフト共重合䜓100重量郚に察しお
0.05〜重量郚、奜たしくは0.1〜重量郚配合
される。たた、前蚘安定剀の他に、安定助剀ずし
お゚ポキシ化倧豆油、゚ポキシ化アマニ油等の゚
ポキシ化怍物油も、前蚘グラフト共重合䜓100重
量郚に察しお30重量郚以䞋、奜たしくは〜20重
量郚配合するこずができる。 さらに、本発明の暹脂組成物においおは、高分
子可塑剀を配合するこずもできる。高分子可塑剀
ずしおは、゚チレン共重合䜓、䟋えば゚チレン−
酢酞ビニル−ケトン共重合䜓〔䟋えば゚ルバロむ
Elvaloy742.E.I.du Pont de Nemours 
Co.補〕、ポリ゚ステル、䟋えばポリカプロラクト
ン−−ポリスチレン、ポリε−カプロラクト
ン〔䟋えばPCL 300、PCL 700以䞊、Union
Carbide瀟補〕ポリ゚ステル〔䟋えばNuoplaz
6187Tenneco Chemicals瀟補、Paraplex −
25、Paraplex −54以䞊Rohm  Haas瀟
補、Admex 761Ashland Chemicals瀟補等〕
等がある。これらのうち、特に前蚘゚チレン共重
合䜓䟋えばElvaloy 742が優れた効果を発揮
する。これらの高分子可塑剀は、前蚘グラフト共
重合䜓100重量郚に察しお150重量郚以䞋、奜たし
くは10〜90重量郚配合される。たた、滑剀やその
他の添加剀も毒性を瀺さない範囲で䜿甚するこず
ができる。 本発明による暹脂組成物は、通垞䞀般に甚いら
れおいるプレス成圢機、抌出成圢機、射出成圢
機、ブロヌ成圢機、むンフレヌシペン成圢機、カ
レンダヌ成圢機等で成圢加工するこずが可胜であ
る。これらの成圢物は、高呚波融着機等を甚い組
立加工するこずにより血液保存容噚が埗られる。 このようにしお埗られる暹脂組成物は透明性が
良奜で柔軟性に富み、耐熱性が良奜で高呚波融着
が可胜で、か぀炭酞ガス透過係数が2.5×103〜9.0
×103ml・mmm2・atm・day30℃奜たしくは
3.0×103〜8.0×103ml・mmm2・atm・day30℃
である。 ぀ぎに、図面を参照しながら、本発明の暹脂組
成物により採血バツグを補造した堎合に぀いお説
明する。すなわち、図血は血液バツグを瀺すもの
で、耇数個のピヌルタブ付き排出口および排出
口を備えた本発明の暹脂組成物補の採血バツグ
は、その呚瞁郚ず高呚波加熱あるいはその他の
加熱手段ひよりヒヌトシヌルされおおり、該採血
バツグ内郚空間に連通する本発明の暹脂組成物
補の採血チナヌブが連結されおいる。この採血
バツグの内郚空間には、抗凝固剀ずしおACD−
液䟋えば、氎溶液100ml䞭にク゚ン酞ナトリ
りム2.20、ク゚ン酞0.80およびブドり糖2.20
含有、CPD液䟋えば、氎溶液100ml䞭にク
゚ン酞0.327、ク゚ン酞ナトリりム2.63、リ
ン酞二氎玠ナトリりム0.251、デキストロヌス
2.32含有等が収玍されおいる。たた、前蚘採
血チナヌブの先端には採血針が取付けられお
いる。この採血針にはキダツプが取付けられ
る。 たた、前蚘採血バツグの他に子バツグを連結
する堎合には、ピヌルタブ付き排出口を備えた
本発明の暹脂組成物補ず同様に呚瞁郚をヒヌ
トシヌルされ、か぀その内郚空間に連通する
本発明の暹脂組成物補のチナヌブを備えた第
の子バツグが分岐管を介しお採血バツ
グの連結甚排出口に、先端の連結針によ
り連結された連結チナヌブず連結される。た
た、ピヌルタブ付き排出口を備えか぀呚瞁郚
を高呚波シヌルされ、その内郚空間に連
通する本発明の暹脂組成物補の連結チナヌブ
を備えた子バツグの前蚘連結チナヌブが
分岐管を介しお連結チナヌブず連
結される。 以䞊は、血液バツグを䟋にず぀お説明したが、
その他の血液保存容噚等に぀いおも同様に䜿甚で
きる。 ぀ぎに、実斜䟋を挙げお本発明をさらに詳现に
説明する。 実斜䟋 〜 第衚に瀺す割合でスチレン−ブタゞ゚ン共重
合䜓分子量75000に塩化ビニルをグラフト重
合しお埗られたグラフト共重合䜓100重量郚に察
しお、゚ポキシ化倧豆油−130P重量郚
およびCa−Zn系安定剀マヌク 593重量郚
を配合しおなる暹脂組成物を抌出成圢しお0.4mm
厚のシヌトを埗た。このシヌトは透明で、溶血毒
性詊隓および现胞毒性詊隓結果は察照液ず同様で
あ぀お、溶血性および现胞毒性は瀺さなか぀た。
たた、炭酞ガス透過性を詊隓したずころ、第衚
のずおりであ぀た。なかでも、実斜䟋〜のも
のは、比范䟋のものよりも時に優れた炭酞ガス
透過性を瀺した。 比范䟋  平均重合床1300のポリ塩化ビニル100重量郚に
察しお゚ポキシ化倧豆油−130P重量郚、
Ca−Zn系安定剀重量郚およびDOP 25重量郹
を配合しお埗られた塩化ビニル暹脂組成物を抌出
成圢しお0.4mm厚のシヌトを埗た。このシヌトに
぀いお実斜䟋〜ず同様な詊隓を行な぀たずこ
ろ、第衚のずおりであ぀た。 比范䟋  平均重合床1300のポリ塩化ビニル100重量郚に
察しお実斜䟋〜で䜿甚したスチレン−ブタゞ
゚ン共重合䜓をそれぞれ実斜䟋〜ず同様な割
合で配合し、この配合物100重量郚に察しお゚ポ
キシ化倧豆油およびCa−Zn系安定剀を同様な割
合で配合しお0.4mm厚のシヌトを埗た。このシヌ
トは機械的匷床が匱く、実甚に適さなか぀た。 実斜䟋 〜10 第衚に瀺す割合でスチレン−ブタゞ゚ン共重
合䜓分子量160000に塩化ビニルをグラフト重
合しお埗られたグラフト共重合䜓100重量郚に察
しお、゚ポキシ化倧豆油−130P重量郚、
Ca−Zn系安定剀マヌク 593重量郚および
スチレン−酢酞ビニル−ケトン共重合䜓゚ルバ
ロむ 74260重量郚を配合しおなる暹脂組成物
を抌出成圢しお0.4mm厚のシヌトを埗た。このシ
ヌトは透明か぀柔軟で、溶血毒性詊隓および现胞
毒性詊隓結果は察照液ず同等であ぀お、溶血性お
よび现胞毒性は瀺さず、血液バツグ甚シヌトずし
お奜適なものであ぀た。たた、炭酞ガス透過性を
詊隓したずころ、第衚のずりであ぀た。なかで
も、実斜䟋〜10のものは、比范䟋のものより
特に優れた炭酞ガス透過性を瀺した。 比范䟋  比范䟋においおDOPの量を50重量郚に増加
した以倖は同様に配合しおシヌトを埗た。このシ
ヌトに぀いお実斜䟋〜10ず同様な詊隓を行な぀
たずころ、第衚のずおりであ぀た。
DETAILED DESCRIPTION OF THE INVENTION BACKGROUND OF THE INVENTION Technical Field The present invention relates to a novel resin composition for blood storage containers. Specifically, the present invention relates to a vinyl chloride-based graft copolymer composition for blood storage containers that has good flexibility and heat resistance, is capable of high-frequency welding, and has excellent gas permeability. Prior Art As is well known, blood has a self-protective effect, and when blood comes into contact with a different interface other than the inner wall of a blood vessel, platelets adhere to the different interface, aggregation, and gelation of plasma, that is, formation of crosslinked fibrin. Formation occurs.
In conventional blood bags, platelets in the blood aggregate to the plastic interface that is the base material of the blood bag, and 6 hours after blood collection, the platelet aggregation ability decreases to about 60% of the time when blood was collected, and after another 24 hours, the platelet aggregation ability decreases to about 60%. It drops to 40%. On the other hand, from the point of view of the effective use of current platelet preparations, it is necessary to develop storage containers made of plastic that can store blood for longer periods of time, storage containers made of so-called blood-compatible plastic, or local medical devices. desired. Currently, plastic containers and other medical devices made of soft vinyl chloride resin are widely used due to their good processability, flexibility, transparency, low water vapor permeability, heat resistance, etc. ing. These soft vinyl chloride resins contain phthalate esters such as di-2-ethylhexyl phthalate (hereinafter referred to as DOP) as plasticizers.
Contains 60%. However, since phthalate esters have a high migration property, it is known that when a blood storage container is made from the above-mentioned soft vinyl chloride resin, the phthalate esters are eluted into blood plasma. For this reason, it has been reported that when phthalate esters dissolve into plasma containing platelet concentrates, they also reduce the aggregation ability, which is a function of platelets. [Japanese Journal of Blood Transfusion 28 , 282 (1982)]. In addition, the soft vinyl chloride resin containing the phthalate ester plasticizer has insufficient gas permeability, and the shelf life of blood bags made using this resin is usually only 6 hours, which is a short period of time. do not have. In other words, soft vinyl chloride resin has a carbon dioxide gas permeability coefficient of approximately 2.0×10 3 ml・mm/m 2・atm・day,
In the blood bag using this, the expiration date of the platelet plasma concentrate was 6 hours. However, this permeability coefficient is 2.5×10 3 to 9.0×10 3 ml・mm/m 2・atm・day
More preferably 3.0×10 3 to 8.0×10 3 mlmm/m 2 .
By using atm-day, the shelf life of platelets was improved, and a pH of 6 or higher, which is considered to be able to effectively preserve platelets, was maintained for more than 72 hours. 2.5
If it is below, the CO 2 concentration generated by platelet metabolism will increase and the PH will decrease, making it impossible to expect long-term preservation of platelets. Also, if it is larger than 9.0,
Platelet metabolism is overactivated and platelet function is likely to be impaired in a short period of time. Note that by keeping the permeability coefficient within the above range, the preservation stability of other blood cells can also be improved. Therefore, if the amount of the plasticizer is increased, gas permeability will be improved, but if the amount is increased, practical mechanical strength will be lost. Therefore, the gas permeability that allows long-term storage of blood cells such as platelets, i.e. 2.5×10 3 to 9.0
It is difficult to obtain ×10 3 ml・mm/m 2・atm・day. On the other hand, polyester plasticizers are used as non-migratory plasticizers. Since this polyester plasticizer is generally composed mainly of fatty acid ester, it is well known that it is inferior to phthalate esters having a phenyl group as a skeleton in terms of water resistance, hydrolysis resistance, etc. On the other hand, as a blood bag material with relatively good gas permeability, 10 to 40% by weight of polypropylene and
A resin composition consisting of a blend with 40 to 85% by weight of a thermoplastic elastomer is known (Japanese Patent Application Laid-open No.
No. 55-60464), such polyolefin resins have poor adhesive properties, so high frequency fusion is difficult during secondary processing, and molding methods are limited. Additionally, it lacks the flexibility that occurs when soft polyvinyl chloride is used. OBJECT OF THE INVENTION Accordingly, an object of the present invention is to provide a novel resin composition for blood storage containers. Another object of the present invention is to provide a vinyl chloride-based graft copolymer composition for blood storage containers that has good flexibility and heat resistance, is capable of high-frequency welding, and has excellent gas permeability. These objectives are such that the amount of styrene-butadiene copolymer and/or its derivative is 20 to 100 parts by weight of the vinyl chloride portion obtained by reacting the styrene-butadiene copolymer and/or its derivative with vinyl chloride. This is achieved by a resin composition for blood storage containers comprising a graft copolymer and a stabilizer in a proportion of 200 parts by weight. The present invention also provides a resin composition for a blood storage container, in which the styrene-butadiene copolymer and/or its derivative portion is 30 to 120 parts by weight based on 100 parts by weight of the vinyl chloride portion. Furthermore, the present invention is a resin composition in which the derivative of the styrene-butadiene copolymer is an epoxidized product, a halide, or a maleated product of the styrene-butadiene copolymer. Also,
The present invention is a resin composition in which the stabilizer is contained in an amount of 0.05 to 5 parts by weight based on 100 parts by weight of the graft copolymer. DETAILED DESCRIPTION OF THE INVENTION The graft copolymer used in the present invention is a new compound, which is obtained by reacting a styrene-butadiene copolymer and/or a derivative thereof with vinyl chloride. The amount of the graft copolymer and/or its derivative portion is from 20 to 200 parts by weight, preferably from 30 to 120 parts by weight. This is because if the amount of the copolymer or its derivative is less than 20 parts by weight, the graft copolymer will have low flexibility, while if it exceeds 200 parts by weight, the mechanical strength will decrease and high frequency fusion will become difficult. It is from. Such a graft copolymer can be produced, for example, by charging vinyl chloride and a styrene-butadiene copolymer or a derivative thereof into a reactor in the above-mentioned proportions, and then subjecting the vinyl chloride to suspension polymerization in the presence of a radical polymerization catalyst. can get. The graft copolymer thus obtained is purified by washing with water or alcohol, if necessary. The styrene-butadiene copolymer used is
The molar ratio of styrene to butadiene is 1:1 to 1:
10, preferably a 1:2 to 1:6 random or block copolymer, the molecular weight of which is 50,000 to 50,000.
200,000, preferably 70,000 to 190,000. Examples include CALIFLEX TR-110 (Ciel Chemical Co., Ltd.), CALIFLEX TR-1107 (Ciel Chemical Co., Ltd.), Solprene (Asahi Kasei Co., Ltd., Philips Co., Ltd.), Tuffprene (Asahi Kasei Co., Ltd.), Clayton G (Ciel Chemical Co., Ltd.), etc. be. Examples of derivatives thereof include epoxides, halides, and maleates of the styrene-butadiene copolymer. Stabilizers blended into the resin composition of the present invention include metals such as calcium and zinc, stearic acid, lauric acid, ricinoleic acid, naphthenic acid,
There are metal soaps with fatty acids such as 2-ethylhexoic acid, and one or more of these are added to 100 parts by weight of the graft copolymer.
It is blended in an amount of 0.05 to 5 parts by weight, preferably 0.1 to 3 parts by weight. In addition to the above-mentioned stabilizers, epoxidized vegetable oils such as epoxidized soybean oil and epoxidized linseed oil may also be used as stabilizing aids, such as 30 parts by weight or less, preferably 5 to 20 parts by weight, per 100 parts by weight of the graft copolymer. Parts by weight can be blended. Furthermore, in the resin composition of the present invention, a polymer plasticizer can also be blended. Examples of polymeric plasticizers include ethylene copolymers, such as ethylene-
Vinyl acetate-ketone copolymers [e.g. Elvaloy 742.
Co., Ltd.], polyesters such as polycaprolactone-g-(polystyrene), polyε-caprolactone [e.g. PCL 300, PCL 700 (and above, Union
Carbide) polyester (e.g. Nuoplaz)
6187 (manufactured by Tenneco Chemicals), Paraplex G-
25, Paraplex G-54 (manufactured by Rohm & Haas), Admex 761 (manufactured by Ashland Chemicals), etc.]
etc. Among these, the above-mentioned ethylene copolymer (eg, Elvaloy 742) exhibits particularly excellent effects. These polymeric plasticizers are blended in an amount of 150 parts by weight or less, preferably 10 to 90 parts by weight, based on 100 parts by weight of the graft copolymer. Furthermore, lubricants and other additives can also be used as long as they do not exhibit toxicity. The resin composition according to the present invention can be molded using commonly used press molding machines, extrusion molding machines, injection molding machines, blow molding machines, inflation molding machines, calendar molding machines, and the like. A blood storage container can be obtained by assembling and processing these molded products using a high frequency fusion machine or the like. The resin composition obtained in this way has good transparency and flexibility, good heat resistance, allows high frequency fusion, and has a carbon dioxide permeability coefficient of 2.5 × 10 3 to 9.0.
×10 3 ml・mm/m 2・atm・day (30℃) preferably
3.0×10 3 ~8.0×10 3 ml・mm/m 2・atm・day (30℃)
It is. Next, a case in which a blood collection bag is manufactured using the resin composition of the present invention will be described with reference to the drawings. That is, the blood sample indicates a blood bag, and the blood collection bag 3 made of the resin composition of the present invention, which is equipped with a plurality of peel-tab-equipped discharge ports 1 and 2, is heated by high-frequency heating or other heating. A blood collection tube 6 made of the resin composition of the present invention is connected to the blood collection bag, which is heat-sealed and communicates with the internal space 5 of the blood collection bag. The internal space of this blood collection bag contains ACD-1 as an anticoagulant.
Solution A (e.g. 2.20 g of sodium citrate, 0.80 g of citric acid and 2.20 g of glucose in 100 ml of aqueous solution)
g), CPD solution (e.g. 0.327 g of citric acid, 2.63 g of sodium citrate, 0.251 g of sodium dihydrogen phosphate, dextrose in 100 ml of aqueous solution)
Contains 2.32g), etc. Further, a blood sampling needle 7 is attached to the tip of the blood sampling tube 6. A cap 8 is attached to this blood collection needle. In addition, when connecting a child bag in addition to the blood collection bag 3, the peripheral part 10 is heat-sealed and the internal space 11 is heat-sealed like the resin composition bag of the present invention equipped with a peel tab-equipped outlet 9. A first child bag 13 having a communicating tube 12 made of the resin composition of the present invention is connected to the connecting outlet 2 of the blood collection bag 3 via a branch pipe 14 by a connecting needle 15 at the tip of the connecting tube. 16. Further, a connecting tube 21 made of the resin composition of the present invention is provided with a discharge port 17 with a peel tab, has a peripheral edge 18 sealed with high frequency, and communicates with the internal space 19.
The connecting tube 21 of the child bag 22 is connected to the connecting tubes 12 and 16 via the branch pipe 14. The above was explained using blood bag as an example,
Other blood storage containers can also be used in the same manner. Next, the present invention will be explained in more detail by giving Examples. Examples 1 to 5 Epoxidized soybean oil (O -130P) and 1 part by weight of a Ca-Zn stabilizer (Mark 593) was extruded to 0.4 mm.
A thick sheet was obtained. The sheet was transparent and the hemolytic and cytotoxicity test results were similar to the control solution, showing no hemolytic or cytotoxic properties.
In addition, carbon dioxide permeability was tested and the results were as shown in Table 1. Among them, those of Examples 2 to 5 sometimes showed better carbon dioxide permeability than that of Comparative Example 1. Comparative Example 1 5 parts by weight of epoxidized soybean oil (O-130P) per 100 parts by weight of polyvinyl chloride with an average degree of polymerization of 1300,
A vinyl chloride resin composition obtained by blending 1 part by weight of a Ca-Zn stabilizer and 25 parts by weight of DOP was extrusion molded to obtain a sheet with a thickness of 0.4 mm. When this sheet was subjected to the same tests as in Examples 1 to 5, the results were as shown in Table 1. Comparative Example 2 The styrene-butadiene copolymers used in Examples 1 to 5 were blended in the same proportions as in Examples 1 to 5 to 100 parts by weight of polyvinyl chloride having an average degree of polymerization of 1300, and this mixture Epoxidized soybean oil and Ca--Zn stabilizer were mixed in the same proportions to parts by weight to obtain a sheet with a thickness of 0.4 mm. This sheet had low mechanical strength and was not suitable for practical use. Examples 6 to 10 Epoxidized soybean oil (O -130P) 5 parts by weight,
A resin composition containing 1 part by weight of Ca-Zn stabilizer (Mark 593) and 60 parts by weight of styrene-vinyl acetate-ketone copolymer (Elvaloy 742) was extruded to obtain a 0.4 mm thick sheet. Ta. This sheet was transparent and flexible, the hemolytic toxicity test and cytotoxicity test results were comparable to the control solution, and it did not exhibit hemolytic or cytotoxic properties, making it suitable as a sheet for blood bags. Further, when carbon dioxide gas permeability was tested, the results were as shown in Table 2. Among them, those of Examples 7 to 10 showed particularly superior carbon dioxide gas permeability than that of Comparative Example 3. Comparative Example 3 A sheet was obtained by blending in the same manner as in Comparative Example 1 except that the amount of DOP was increased to 50 parts by weight. When this sheet was subjected to the same tests as in Examples 6 to 10, the results were as shown in Table 2.

【衚】【table】

【衚】 実斜䟋 11 本発明による暹脂組成物のガス透過性向䞊効果
をみるために、実斜䟋の暹脂組成物ずスチレン
−ブタゞ゚ン共重合䜓ずが同䞀比率ずなるよう
に、ポリ塩化ビニルずスチレン−ブタゞ゚ン共重
合䜓ずをテトラヒドロフラン䞭で溶解混合し、メ
タノヌルで再沈柱を行ない、第衚に瀺す比率で
゚ポキシ化倧豆油、Ca−Zn系安定剀および゚ル
バロむ 742を配合しお0.4mm厚のシヌトを䜜補
し、炭酞ガス透過係数を枬定したずころ、第衚
のずおりであ぀た。
[Table] Example 11 In order to examine the effect of improving gas permeability of the resin composition according to the present invention, polyvinyl chloride and polyvinyl chloride were mixed so that the resin composition of Example 9 and the styrene-butadiene copolymer were in the same ratio. Styrene-butadiene copolymer was dissolved and mixed in tetrahydrofuran, reprecipitated with methanol, and epoxidized soybean oil, Ca-Zn stabilizer, and Elvaloy 742 were blended in the ratio shown in Table 3, and the mixture was mixed to a thickness of 0.4 mm. A sheet was prepared and the carbon dioxide permeability coefficient was measured, and the results were as shown in Table 3.

【衚】 実斜䟋 12 実斜䟋のシヌトず、比范䟋のシヌトに぀い
お、シヌト衚面の血小板の付着数および圢態の分
離を枬定したずころ、第衚のずおりであ぀た。 第衚 実斜䟋 比范䟋 総付着数 157 257 総付着数䞭の型の数 66 113 型の割合 42 44 実隓法 詊料衚面に9.5䞇個mm3の血小板浮遊液を滎䞋
し、30分間攟眮埌の血小板の付着数および付着血
小板の圢態倉化を芳察した。なお、分類評䟡のう
ち、型ずは、血小板が拡匵しおいお平板䞊にな
぀おいるものである。 実斜䟋 13 実斜䟋の暹脂組成物ず比范䟋の暹脂組成物
ずでそれぞれ厚さ0.4mmのシヌトを䜜補し、さら
に高呚波融着しおバツグを䜜補した。このバツグ
にACD−液を保存液ずしお、濃瞮血小板血挿
をml入れ、22℃で72時間保存した堎合の該シヌ
トの炭酞ガス透過性ずPH倉化ずを芳察したずこ
ろ、第衚の結果を埗た。
[Table] Example 12 Regarding the sheet of Example 8 and the sheet of Comparative Example 3, the number of platelets attached to the sheet surface and the separation of their morphology were measured, and the results were as shown in Table 4. Table 4 Example 8 Comparative Example 3 Total number of adherents 157 257 Number of molds in total number of adherents 66 113 Percentage of molds (%) 42 44 Experimental method 95,000/mm 3 platelet suspension was dropped onto the sample surface. The number of attached platelets and morphological changes of attached platelets were observed after leaving for 30 minutes. In addition, in the classification evaluation, the platelet type is one in which the platelets are expanded and formed on a flat plate. Example 13 Sheets each having a thickness of 0.4 mm were prepared from the resin composition of Example 8 and the resin composition of Comparative Example 3, and then high frequency welded to form bags. 3 ml of concentrated platelet plasma was added to this bag using ACD-A solution as a storage solution, and when the sheet was stored at 22°C for 72 hours, the carbon dioxide gas permeability and PH changes of the sheet were observed, and the results shown in Table 5 were obtained. Obtained.

【衚】 血小板保存䞭のPHの維持は、茞血液の血小板生
存率に重芁な意味をも぀おおり、本発明の実斜䟋
のようにしお炭酞ガス透過性の高いバツグで保
存した堎合、PHの䜎䞋が比范䟋のものより小さ
く、血小板保存䞭の機胜維持がよいこずは明癜で
ある。 発明の具䜓的効果 以䞊述べたように、本発明による血液保存容噚
甚暹脂組成物は、スチレン−ブタゞ゚ン共重合䜓
およびたたはその誘導䜓に塩化ビニルを反応さ
せお埗られる塩化ビニル郚分100重量郚に察しお
スチレン−ブタゞ゚ン共重合䜓およびたたはそ
の誘導䜓郚分が20〜200重量郚、奜たしくは〜
120重量郚の割合であるグラフト共重合䜓および
安定剀よりなるものであるから、柔軟性および耐
熱性が良奜でか぀高呚波融着が可胜で、さらに気
䜓透過性、特に炭酞ガス透過性に優れおいる。た
た、塩化ビニル郚分100重量郚に察しおスチレン
−ブタゞ゚ン共重合䜓およびたたはその誘導䜓
郚分が20〜200重量郚、奜たしくは30〜120重量郹
であるので、特に炭酞ガス透過性が良奜である。
さらに、本発明による暹脂組成物は、溶血毒性な
らびに现胞毒性がなく、か぀血小板付着および圢
態倉化が小さく、しかもPH倉化が小さいので、血
液バツグ等の医療甚具甚材料ずしお極めお有甚で
ある。たた、野菜等の代謝を行なう内容物の包装
材料ずしお有甚である。
[Table] Maintaining the PH during platelet storage has an important meaning for the platelet survival rate of transfused blood. It is clear that the decrease in the value was smaller than that of Comparative Example 3, and that the function was maintained well during platelet storage. Specific Effects of the Invention As described above, the resin composition for blood storage containers according to the present invention is characterized in that 100 parts by weight of vinyl chloride is obtained by reacting vinyl chloride with a styrene-butadiene copolymer and/or a derivative thereof. 20 to 200 parts by weight of the styrene-butadiene copolymer and/or its derivative, preferably 0 to 200 parts by weight.
Since it is composed of 120 parts by weight of a graft copolymer and a stabilizer, it has good flexibility and heat resistance, is capable of high frequency welding, and has excellent gas permeability, especially carbon dioxide gas permeability. There is. In addition, since the styrene-butadiene copolymer and/or its derivative portion is 20 to 200 parts by weight, preferably 30 to 120 parts by weight, per 100 parts by weight of the vinyl chloride portion, carbon dioxide gas permeability is particularly good. .
Further, the resin composition according to the present invention is free of hemolytic toxicity and cytotoxicity, has low platelet adhesion and morphological change, and has low PH change, and is therefore extremely useful as a material for medical devices such as blood bags. It is also useful as a packaging material for contents that undergo metabolism, such as vegetables.

【図面の簡単な説明】[Brief explanation of drawings]

図面は、本発明による暹脂組成物を甚いた医療
甚具の䞀䟋を瀺す正面図である。   血液バツグ、  子バツグ、
  チナヌブ。
The drawing is a front view showing an example of a medical device using the resin composition according to the present invention. 3...Blood bug, 13,22...Child bug,
6, 16, 21...Tube.

Claims (1)

【特蚱請求の範囲】  スチレン−ブタゞ゚ン共重合䜓およびたた
はその誘導䜓に塩化ビニルを反応させお埗られる
塩化ビニル郚分100重量郚に察しおスチレン−ブ
タゞ゚ン重合䜓およびたたはその誘導䜓郚分が
20〜200重量郚の割合であるグラフト共重合䜓お
よび安定剀よりなる血液保存容噚甚暹脂組成物。  スチレン−ブタゞ゚ン共重合䜓の誘導䜓がス
チレン−ブタゞ゚ン共重合䜓の゚ポキシ化物、ハ
ロゲン化物たたはマレむン化物である特蚱請求の
範囲第項に蚘茉の血液保存容噚甚暹脂組成物。  グラフト共重合䜓100重量郚に察しお安定剀
が0.05〜重量郚配合されおなる特蚱請求の範囲
第項たたは第項に蚘茉の血液保存容噚甚暹脂
組成物。  炭酞ガス透過係数が2.5×103〜9.0×103ml・
mmm2・atm・dayである特蚱請求の範囲第項
ないし第項のいずれか䞀぀に蚘茉の血液保存容
噚甚暹脂組成物。
[Scope of Claims] 1. The styrene-butadiene copolymer and/or its derivative portion is based on 100 parts by weight of the vinyl chloride portion obtained by reacting the styrene-butadiene copolymer and/or its derivative with vinyl chloride.
A resin composition for a blood storage container comprising a graft copolymer and a stabilizer in a proportion of 20 to 200 parts by weight. 2. The resin composition for a blood storage container according to claim 1, wherein the derivative of the styrene-butadiene copolymer is an epoxidized product, a halide, or a maleated product of the styrene-butadiene copolymer. 3. The resin composition for a blood storage container according to claim 1 or 2, which contains 0.05 to 5 parts by weight of a stabilizer based on 100 parts by weight of the graft copolymer. 4 Carbon dioxide permeability coefficient is 2.5×10 3 to 9.0×10 3 ml・
The resin composition for a blood storage container according to any one of claims 1 to 3, which has a particle size of mm/m 2 ·atm ·day.
JP58062239A 1983-04-11 1983-04-11 Resin composition Granted JPS59189153A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58062239A JPS59189153A (en) 1983-04-11 1983-04-11 Resin composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58062239A JPS59189153A (en) 1983-04-11 1983-04-11 Resin composition

Publications (2)

Publication Number Publication Date
JPS59189153A JPS59189153A (en) 1984-10-26
JPH0356739B2 true JPH0356739B2 (en) 1991-08-29

Family

ID=13194396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58062239A Granted JPS59189153A (en) 1983-04-11 1983-04-11 Resin composition

Country Status (1)

Country Link
JP (1) JPS59189153A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357940B2 (en) * 2003-07-31 2008-04-15 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing graft copolymer for controlled delivery of therapeutic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL57233A (en) * 1978-06-29 1981-12-31 Stauffer Chemical Co Homogenizer process for forming emulsion/suspension polymers

Also Published As

Publication number Publication date
JPS59189153A (en) 1984-10-26

Similar Documents

Publication Publication Date Title
US5026347A (en) Plastic composition with anti-hemolytic effect
US5167657A (en) Plastic composition with anti-hemolytic effect
US5100401A (en) Plastic composition with anti-hemolytic effect
EP0230744B1 (en) Propylene polymer composition
JPH0136384B2 (en)
EP0340305B1 (en) Hemolysis inhibitor and plasticizer
WO1993014810A2 (en) Material for medical grade products and products made therefrom
EP0778030B1 (en) Container for medical use
US5248531A (en) Hemolysis depressant and plasticizer
US4329992A (en) Medical apparatus for parenteral liquids
AU623071B2 (en) Hemolysis inhibitor and medical resin composition, medical implement, and blood-preserving fluid containing the same
JPH0356739B2 (en)
EP0409155A2 (en) Bag for storage of platelets and multiple bag system containing the bag
JPS6158191B2 (en)
EP0108955B1 (en) Medical articles
JPH0149303B2 (en)
EP0330151A2 (en) Bag for the storage of blood platelets
JP2007130503A (en) Blood component storage container and blood component storage device connected with blood component storage container
JPS6158192B2 (en)
JPS5967960A (en) Blood preserving container
JPH0422363A (en) Bag for preserving platelet and composite bag using the same
JPH02211160A (en) Blood bag
JPH04210061A (en) Platelet preserving container
JPH01104264A (en) Medical soft resin composition and medical utensil
JPH0611287B2 (en) Platelet storage bag and composite bag using the same